It won’t do what everyone wants it to do and what our governments say is needed to put an end to restrictions.
Health Coronavirus 2020 / Worldwide (Stats live update in OP) Part 4
- Thread starter Gralin
- Start date
- Tagged users None
- Status
Number one reason given at triage is being forced to watch too many Mark McGowan press conferences
Gralin
Super Moderator
- Thread starter
- Moderator
- #6,030
Yeah so if there's numbers are accurate we've got enough to vaccinate everyone though most will get the Oxford one, as far as I know they are all two step vaccines.
They were reporting somewhere that we'd be getting about 1m doses a week of Oxford from March or April, with an initial batch of 3m
www.abc.net.au
Either way I wouldn't be expecting the program to cover enough of the population for 6+ Months
They were reporting somewhere that we'd be getting about 1m doses a week of Oxford from March or April, with an initial batch of 3m
Most people in Australia likely to get AstraZeneca COVID vaccine rather than Pfizer shot
While the Pfizer-BioNTech COVID-19 vaccine will likely be the first to get approval in Australia, most of us will end up receiving the Oxford-AstraZeneca shot, Chief Medical Officer Paul Kelly says.
Either way I wouldn't be expecting the program to cover enough of the population for 6+ Months
Gough
Moderator
- Sep 29, 2006
- 72,041
- 133,784
- AFL Club
- Hawthorn
- Moderator
- #6,031
The copper wired NBN of vaccines.Yeah so if there's numbers are accurate we've got enough to vaccinate everyone though most will get the Oxford one, as far as I know they are all two step vaccines.
They were reporting somewhere that we'd be getting about 1m doses a week of Oxford from March or April, with an initial batch of 3m
Most people in Australia likely to get AstraZeneca COVID vaccine rather than Pfizer shot
While the Pfizer-BioNTech COVID-19 vaccine will likely be the first to get approval in Australia, most of us will end up receiving the Oxford-AstraZeneca shot, Chief Medical Officer Paul Kelly says.
Either way I wouldn't be expecting the program to cover enough of the population for 6+ Months
I believe the plan is to use Pfizer for the front-line workers and those most vulnerable, and then later cover the rest of the population with the less effective Oxford vaccine, which they'll be able to manufacture here at a high volume for much cheaper than the cost of acquiring Pfizer and without the logistical problems.
Feels a bit like that, honestly. Half-step approach to save money that might cost us in the long run.
That said, in practice the claimed effectiveness of Pfizer is in some doubt so maybe there might not ultimately be that much of a difference between the two. There's still not enough known about any of them in the real world to know what approach is best, but certainly the government has hedged its bets on the cheapest, most convenient option being the most appropriate.
It's effectiveness after the second jab that's important. Not the vaccine or manufacturer's problem that some decided to go against the explicit advice of administering the two doses close together, instead opting to try to give more people the first dose and delay the second.
Gralin
Super Moderator
- Thread starter
- Moderator
- #6,036
It's important in that if they claim 90% from a single dose and in reality we are seeing much lower that it's a tinder that the published efficacy rates currently aren't proof of one vaccine being better than another.
Pfizer appears to be the best but it's also the hardest to distribute effectively.
This is a numbers game, the more people you can reduce severity for the more quickly you can do it the better.
If we have to rely on overseas manufacturing and transport for supply of Pfizer that's a risk we do t have with one we can manufacture and distribute locally.
I'm not saying they've made a good call here but talk about the whole situation
- Jun 20, 2011
- 2,674
- 2,676
- AFL Club
- Gold Coast
33% effective over what timeframe?
This study shows no effect for the first 2 weeks, then >60% effectiveness after 3 weeks.
You're right, it's a concern. As I said above we can't make any definitive statements about effectiveness just yet. We only have rushed trial results and now limited vaccination numbers in other nations. Could be, and hopefully does prove true, that Pfizer's effectiveness increases significantly on the second dose. Could be it falls down in line with Oxford's effectiveness, and that makes the government's plan a winner if so because it is much more convenient for us.
But despite trial results, the government made a decision based on cost, much like they did the NBN. That potentially the best contender couldn't live up to its claims would be just a lucky break for them rather than based on decision-making processes looking for the absolute best outcome for everyone.
- Jun 20, 2011
- 2,674
- 2,676
- AFL Club
- Gold Coast
Do you have any evidence that this based on cost, and not just a the result of limited supply?
- Nov 17, 2007
- 18,659
- 22,881
- AFL Club
- Richmond
The reason the Oxford dose is less than half the price of its nearest competitor is they decided at the outset that it would be non-profit, to benefit the world.
- Jun 20, 2011
- 2,674
- 2,676
- AFL Club
- Gold Coast
No, the primary reason that it is cheaper because its use established technology for which mass manufacturing capability already exists.
Gralin
Super Moderator
- Thread starter
- Moderator
- #6,042
Initial Israeli data: First Pfizer shot curbs infections by 50% after 14 days
Studies of hundreds of thousands of Israeli vaccinees provide real-world info on efficacy; but health official also warns 17% of current serious cases had already gotten 1st shot
www.timesofisrael.com
Onshore manufacturing is looking more beneficial with the global supply issues. Hopefully this leads to better access for the Pacific Islands and also can be used to assist Indonesia if necessary.
What is happening with New Zealand? They seem to be waiting far longer than even us?
What is happening with New Zealand? They seem to be waiting far longer than even us?
I'm curious to know if the supposed lethality increase of new covid strains factors in the substandard treatment from an overloaded health system. It's hard not to imagine an increase in lethality when people are turned away, oxygen is rationed, etc.
- Sep 15, 2011
- 31,686
- 48,275
- AFL Club
- West Coast
Even more insignificant than us globally.
Pakenhamsaint
Premium Platinum
- Jan 5, 2011
- 46,260
- 37,723
- AFL Club
- St Kilda
Meanwhile the Pfizer vaccine has been provisionally approved by the TGA.
- Jun 22, 2008
- 24,580
- 21,276
- AFL Club
- Geelong
By 1990, no Australian child will be living in poverty.
Going on Hawke's pledge, Morrison has 31 years and counting to get them all home.
- Nov 17, 2007
- 18,659
- 22,881
- AFL Club
- Richmond
This is on lots of local news sites, has not been picked up by MSM yet except by an ABC(US) regional station:
A judge ordered the Millard Fillmore Suburban Hospital in Buffalo, NY to allow an 80-year old woman to be treated with Ivermectin. According to the family their attorney, the treatment saved the life of Judith Smentkiewicz. Although not yet approved, according to court documents, the woman’s daughter referred to it as a “miracle drug,” as do her attorneys, Ralph C. Lorigo and Jon F. Minear. Apparently, a doctor ordered the drug off-label in the intensive care unit (ICU), and as she improved, she was moved to another unit, and the doctor there stepped in and disallowed the use of the drug. Family members immediately involved lawyers and legal action to resume treatment. And now, The New York Supreme Court Judge Henry J. Nowak has aligned with the family.
After resuming treatment she has recovered and been sent home.
Apart from the study of ivermectin on 24 patients in Barcelona last year, another study has been completed in Lagos, Nigeria involving 62 patients, with positive results in mild-moderate cases. FWIW I'm encouraged that they are doing it. IMO the numbers are way too low to get solid results, but I'm not a researcher so what do I know.
www.medrxiv.org
A judge ordered the Millard Fillmore Suburban Hospital in Buffalo, NY to allow an 80-year old woman to be treated with Ivermectin. According to the family their attorney, the treatment saved the life of Judith Smentkiewicz. Although not yet approved, according to court documents, the woman’s daughter referred to it as a “miracle drug,” as do her attorneys, Ralph C. Lorigo and Jon F. Minear. Apparently, a doctor ordered the drug off-label in the intensive care unit (ICU), and as she improved, she was moved to another unit, and the doctor there stepped in and disallowed the use of the drug. Family members immediately involved lawyers and legal action to resume treatment. And now, The New York Supreme Court Judge Henry J. Nowak has aligned with the family.
After resuming treatment she has recovered and been sent home.
Apart from the study of ivermectin on 24 patients in Barcelona last year, another study has been completed in Lagos, Nigeria involving 62 patients, with positive results in mild-moderate cases. FWIW I'm encouraged that they are doing it. IMO the numbers are way too low to get solid results, but I'm not a researcher so what do I know.
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos
Introduction In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV-2 viral replication, but questions remained as to In-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. Methods We conducted a...
- Jun 20, 2011
- 2,674
- 2,676
- AFL Club
- Gold Coast
Also not a researcher, but I would suggest the only value of those studies is provide support for undertaking further large scale studies. Other drugs have had studies showing improved recovery times, but ultimately have failed to have any meaningful impact of number of patients requiring hospitalization / survival rates (i.e. Remdesivir) what is what actually matters.Apart from the study of ivermectin on 24 patients in Barcelona last year, another study has been completed in Lagos, Nigeria involving 62 patients, with positive results in mild-moderate cases. FWIW I'm encouraged that they are doing it. IMO the numbers are way too low to get solid results, but I'm not a researcher so what do I know.
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos
Introduction In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV-2 viral replication, but questions remained as to In-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. Methods We conducted a...
Forward Press
Hall of Famer
If a drug is well known to be and proven safe (eg Remdesivir) and widely available (ie does not mean those who need it for its approved uses are denied or being forced to pay more), I don't see the issue with giving it a go, and continuing with it if the patient continues to improve, or with further study into its effectiveness as a possible treatment.
The problem is when governments start touting it as a miracle drug and it leads to hoarding and unnecessary injury and death.
- Status
Similar threads
- Locked
